The major terminal enzymatic expression of the fibrinolytic cascade system in vivo is plasmin. This enzyme is piesumed to interact with fibrinogen and fibrin in vivo and is arguably man's major defence against the deposition of fibrin, an important component in the general hazard of thrombosis.
Our understanding of the molecular details of plasmin interactions with fibrinogen and fibrin has been established over the past 10 years. As a part of the overall strategy to elaborate the primary sequence of human fibrinogen the precise locations of the peptide bonds ruptured by plasmin at various stages in the degradation process have been reported. Such precise data are not available as yet for fibrinplasmin interactions. I shall discuss the major aspects of fibrinogen-plasmin interactions only briefly since these have been recently reviewed by, among others, Mosesson and Finlayson1 and Gaffney.2 I shall deal with the current knowledge of fibrin-plasmin interactions in more detail since new and exciting data concerning fibrin fragmentation, which may have significance in vivo, have recently emerged.
In this review I am supposing that the major breakdown products of fibrinogen and fibrin (FDPs) are mediated by plasmin in vivo. Thus the in-vitro experiments conducted in many laboratories over the years have concentrated on plasmin-mediated interactions. It is, however, well to point out that the interactions between fibrinogen and a number of other proteolytic enzymes have also been studied in vitro (for review see Latallo et al.3) . Indeed, Moroz and Gilmore4 thought that a variety of proteolytic enzymes of cellular origin may play a far more important part in the lysis of established thrombin in vivo than does plasmin. Nevertheless, there is little doubt that plasmin interacts with forming fibrin, attempting to prevent its deposition on the vessel wall. I shall expand this last opinion when discussing plasmin-fibrin interactions and their significance in vivo. In view of the evidence that the D dimer-E complex is a major product of cross-linked fibrin lysis in vivo,5051 a variety of lytic regimens was investigated to determine whether this complex was the earliest soluble expression of XL-fibrin lysis.
It transpired that besides the D dimer-E complex higher molecular weight complexes are released from XL-FN which have been classified as crosslinked fragment X-oligomers, Y-D, and D dimer complexes. Schematic structures of these fibrin degradation products (Fig. 4) 54 Our unpublished data also indicate that the cross-linked X-oligomeis are the first fragments derived from XL-fibrin by plasmin, are the precursors of the D dimer-E complex, and are present during lysis of fibrin performed under near-physiological conditions in vitro. These oligomers have also been isolated from the plasma of patients during episodes of fulminant disseminated intravascular coagulation (DIG)54 and other forms of intravascular coagulation. 55 The molecular interactions which allow the XL X-oligomers to be formed during DIC are rather difficult to interpret in the light of our understanding of the formation of such high molecular weight derivatives from a XL-FN clot. The scheme outlined in It is also proposed that such fragments should be formed during the lysis ofpreformed thrombi in vivo since they are present during the lysis of XL-fibrin in vivo under near-physiological conditions. FG = fibrinogen; FN = fibrin; the X derivatives of both FG and FN are formed by the PL-mediated removal of peptide material from the carboxy terminal ends of the Aca and cx chains (see Fig. 1 ). It is surmised that during DIC these reactions take place in solution without deposition offibrin.
our thoughts with those of Graeff and his colleagues55 and suggests that the XL X-oligomers could occur by a number of pathways which involve the competition of plasmin and thrombin for fibrinogen and fibrin during DIC. It seems that the earliest fragments formed during fibrin clot lysis procoagulant from the venom of Agkistrodon rhodostoma. Coagulation disorders (mostly DIC) in obstetric patients were accompanied by the presence in the plasma of large fibrin fragments similar to the X-oligomers described above in the XL-fibrin digests,55 while cases of fulminant DIC had crosslinked X-oligomers and the D dimer-E complex in the plasma. 51 Emerging from case reports such as those referred to above is a hypothesis (Fig. 6) The hypothesis presented in Fig. 6 suggests that the composition of the fragments formed during the competition between thrombin and plasmin should shed light on the severity of the so-called hypercoagulable state in the patient's blood. The presence of non-cross-linked fragments would suggest that the fibrinolytic system was rapidly digesting forming fibrin, whereas large cross-linked fragments (X-oligomers) together with cross-linked D dimer-E, Y-Y, and Y-D complexes would suggest that the hypercoagulability was quite severe in that the fibrinolytic system was being overpowered and barely coping with the fibrin polymerisation process. The latter instance could be detected by sensitive assays for these high molecular weight cross-linked complexes, and such assays might be useful in highlighting the clinically-dangerous hypercoagulable or thrombotic state.
Similar concepts about the haemostatic balance during DIC have been outlined by others62 using assay procedures for fibrinopeptide A and the NH2-terminal B,B peptide (1-42) to determine the influence of thrombin and plasmin respectively. We believe, however, that the presence of the crosslinked fragments described above (and shown in Figs. 4 and 6) in a patient's plasma would indicate a more advanced state of hypercoagulability than would be detected by the tests suggested by Nossel and colleagues.63 Whereas these cross-linked fragments have been found in the plasma of patients during DIC, assays have yet to be developed of sufficient sensitivity to monitor their presence in plasma during thrombolytic therapy for thrombosis. To this end antisera have been raised in rabbits which contain conformational neo-antigens for the cross-linked X-oligomers. These antisera do not react with fibrinogen and their use is contemplated in radioimmunoassay to detect the advanced prethrombotic state and to clarify the role of fibrinolysis as man's major defence against thrombosis. extends the thoughts of Astrup6' about coagulation and fibrinolysis being systemically balanced to maintain blood fluidity and competent haemostasis. It is now more probable that this balance operates at a local rather than a systemic level. The amount of available thrombin depends on the amount of circulating inhibitors (notably At III) which operate at various points in the coagulation cascade. The amount of plasmin available for fibrin digestion seems to be independent of the concentrations of fibrinolytic inhibitors (notably the fast-acting a,2-antiplasmin) since plasminogen seems to be protected from inhibition by the forming fibrin polymers.
